After several promising studies, commercially available devices for bed-side assessment of urinary [TIMP-2] × [IGFBP-7] became available, and received clearance by the US food and drug administration (FDA) for clinical use as an aid, but not as a stand-alone test, in risk assessment of AKI. This evidence concerns the gene IGFBP7 and acute kidney injury.